Earnings Outlook For Halozyme Therapeutics

Halozyme Therapeutics (NASDAQ:HALO) is preparing to release its quarterly earnings on Tuesday, 2025-08-05. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Halozyme Therapeutics to report an earnings per share (EPS) of $1.20.

Anticipation surrounds Halozyme Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Earnings History Snapshot

Last quarter the company beat EPS by $0.17, which was followed by a 18.12% increase in the share price the next day.

Here's a look at Halozyme Therapeutics's past performance and the resulting price change:

Quarter

Q1 2025

Q4 2024

Q3 2024

Q2 2024

EPS Estimate

0.94

1.16

0.98

0.78

EPS Actual

1.11

1.26

1.27

0.91

Price Change %

18.0%

-0.0%

13.0%

4.0%

Market Performance of Halozyme Therapeutics's Stock

Shares of Halozyme Therapeutics were trading at $59.02 as of August 01. Over the last 52-week period, shares are up 13.85%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Analysts' Take on Halozyme Therapeutics

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Halozyme Therapeutics.

Halozyme Therapeutics has received a total of 5 ratings from analysts, ...